MSJ 650
Alternative Names: MSJ-650Latest Information Update: 05 Jul 2024
At a glance
- Originator SillaJen Biotherapeutics
- Class Antineoplastics; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Breast cancer; Colorectal cancer
Most Recent Events
- 05 Apr 2024 Preclinical trials in Breast cancer in South Korea (IV)
- 05 Apr 2024 Preclinical trials in Colorectal cancer in South Africa (IV) before April 2024
- 05 Apr 2024 Pharmacodynamics data from a preclinical trial in Colorectal cancer presented at the 115th Annual Meeting of the American Association for Cancer Research(AACR-2024)